E.N. BEZZUBTSEVA, L.V. VASILYEVA, E.V. GOSTEVA, M.N. LATYSHEVA, E.YU. SUSLOVA

 Voronezh State Medical University named after N. N. Burdenko, Voronezh

 Contact details:

Bezzubtseva E.N. — post-graduate student of the Deprtment of Propedeutics of Internal Diseases

Address: 10 Studencheskaya St., Voronezh, Russian Federation, 394036, tel.: +7-952-103-76-94, e-mail: bezzubtsewa.ekaterina@yandex.ru

Pulmonogenic osteopenia, which can be detected by blood markers of bone tissue resorption (C-terminal collagen-1 telopeptide), markers of bone tissue formation (osteocalcin, alkaline phosphatase), regulators of osteoclastogenesis (osteoprotegerin), and parathyroid hormone, develops in patients with COPD, especially comorbid metabolic syndrome (MS). They are formed as a result of systemic inflammation, which is characterized by hyperproduction of adipokines (resistin) and indicators of systemic inflammation (TNF-α, IL-4, IL-6, IL-18). Among such patients, a special category consists of individuals with polymorphisms of candidate genes that determine bone mineral density. Accordingly, the combination of the above-mentioned modifiable and unmodifiable risk factors leads to an increase in the incidence of fractures of both vertebrogenic and non-vertebrogenic localization, which enhances the medical and social significance of this pathology. 110 people were examined: 20 of them made up the control group, 45 were included in the COPD group and 45 in the group of COPD combined with metabolic syndrome (COPD + MS). In patients of the studied groups, a genetic study was conducted to identify polymorphism of the calcitonin receptor gene CALCR, to determine indicators of systemic inflammation of tumor necrosis factor alpha (TNF-α), interleukin 4 (IL-4), interleukin-6 (IL-4), interleukin-18 (IL-18), markers of bone metabolism: beta- terminal C-telopeptide of collagen-1 (β-CTx), osteocalcin (OC), alkaline phosphatase (ALP), osteoprotegerin (OP), parathyroid hormone (PTH). In patients with COPD combined with metabolic syndrome, a high frequency of occurrence of pathological alleles Leu/Leu- calcitonin receptor gene (CALCR) was revealed. The levels of markers of systemic inflammation and bone metabolism were significantly higher in the group of patients with COPD+MS. Significant relationships were revealed between the indicators of FEV1, T-criterion, TNF-α, IL-6, VAS, β- STx, PTH and functional defective alleles of Leu/Leu in patients with COPD+MS.

Key words: chronic obstructive pulmonary disease, osteoporosis, calcitonin receptor gene, osteocalcin, osteoproheterin, alkaline phosphatase.

REFERENCES

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2020, available at: https://goldcopd.org/
2. Rothnie K.J., Connell O., Müllerová H. et al. Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc, 2018, vol. 15 (8), pp. 935–946. DOI: 10.1513/AnnalsATS.201710-815OC
3. Hopkins R.J., Duan F., Chiles C. et al. Expiratory Flow Rate among Heavy Smokers Increases Lung Cancer Risk. Results from the National Lung Screening Trial-American College of Radiology Imaging Network Cohort. Ann Am Thorac Soc, 2017, vol. 14 (3), pp. 392–402. DOI: 10.1513/AnnalsATS.201609-741OC
4. Montserrat-Capdevila J., Godoy P., Marsal J.R., Barbé F. et.al. Overview of the Impact of Depression and Anxiety in Chronic Obstructive Pulmonary Disease. Lung, 2017, vol. 195 (1), pp. 77–85. DOI: 10.1007/s00408-016-9966-0
5. Singh B., Parsaik A.K., Mielke M.M. et al. Chronic obstructive pulmonary disease and association with mild cognitive impairment: The Mayo Clinic Study of Aging. Mayo Clin Proc, 2013, vol. 88 (11), pp. 1222–1230. DOI: 10.1016/j.mayocp.2013.08.012
6. Nikitin A.V., Vasil’eva L.V., Evstratova E.F., Nikitin V.A. Prognostic value of bone density characteristics in patients with chronic obstructive pulmonary disease. Klin. med., 2017, vol. 95 (12), pp. 1094–1097 DOI: 10.18821/0023-2149-2017-95-12-1094-1097
7. Baranova I.A., Suleymanova A.K. Osteoporosis and low-energy fractures in pulmonary patients: focus on chronic obstructive pulmonary disease. Effektivnaya farmakoterapiya, 2020, vol. 16, no. 19, pp. 52–57 (in Russ.). DOI: 10.33978/2307-3586-2020-16-19-52-57
8. Yan L., Hu R., Tu S., Cheng W.J. et al. Meta-analysis of association between IL-6 -634C/G polymorphism and osteoporosis. Genet Mol Res, 2015, vol. 14 (4), pp. 19225–19232. DOI: 10.4238/2015
9. Vasil’eva L.V., Evstratova E.F., Nikitin V.A., Latysheva M.N. Pathogenetic mechanisms of treatment of pain in the lumbar region caused by osteoporosis of mixed genesis in patients with chronic obstructive pulmonary disease. Farmateka, 2019, no. 26 (5), pp. 92–96 (in Russ.).
10. Zhila I.E., Bogdanova E.O., Zhila O.V., Shaporova N.L., Dudina O.V., Batagov S.Ya. Features of the course of osteoporosis in patients with chronic obstructive pulmonary disease. Pul’monologiya, 2016, no. 26 (1), pp. 46–51 (in Russ.).
11. Tsai D.J., Fang W.H., Wu L.W., Tai M.C.et al. The Polymorphism at PLCB4 Promoter (rs6086746) Changes the Binding Affinity of RUNX2 and Affects Osteoporosis Susceptibility: An Analysis of Bioinformatics-Based Case-Control Study and Functional Validation. Front Endocrinol (Lausanne), 2021, vol. 12, p. 730686. DOI: 10.3389/fendo.2021.730686 PMID: 34899595; PMCID: PMC8657146.
12. Zhu D.L., Chen X.F., Hu W.X. et al. Multiple Functional Variants at 13q14 Risk Locus for Osteoporosis Regulate RANKL Expression Through Long-Range Super-Enhancer. J Bone Miner Res, 2018, vol. 33 (7), pp. 1335–1346. DOI: 10.1002/jbmr.3419 Epub 2018 May 17. PMID: 29528523.
13. Li M., Yao S., Duan Y.Y., Zhang Y.J. et al. Transcription Factor Enrichment Analysis in Enhancers Identifies EZH2 as a Susceptibility Gene for Osteoporosis. J Clin Endocrinol Metab, 2020, vol. 105 (4), p. dgz270. DOI: 10.1210/clinem/dgz270 PMID: 31833556.
14. Nakamura M., Zhang Z.Q., Shan L. et al. Allelic variants of human calcitonin receptor in the Japanese population. Hum Genet, 1997, vol. 99 (1), pp. 38–41. DOI: 10.1007/s004390050307
15. Shilina N.M., Sorokina E.Yu., Ivanushkina T.A. et al. Study of the rs11801197 polymorphism of the calcitonin receptor gene (CALCR) in women and children of Moscow with different levels of bone strength. Vopr. pitaniya, 2017, vol. 86, no. 1, pp. 28–34 (in Russ.).
16. Pennisi P., Signorelli S., Riccobene S. et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos. Int, 2004, vol. 15, pp. 389–395. DOI: 10.1007/s00198-003-1550-9
17. Masheyko I.V. Biochemical markers in assessing the processes of bone tissue remodeling in osteopenia and osteoporosis. Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta, 2017, no. 2, pp. 149–153 (in Russ.).
18. Belenkov Yu.N., Privalova E.V., Kaplunova V.Yu. et al. Metabolic syndrome: history of development, main diagnostic criteria. Ratsional’naya farmakoterapiya v kardiologii, 2018, no. 14 (5), pp. 757–764 (in Russ.). DOI: 10.20996/1819-6446-2018-14-5-757-764
19. Chernova T.O., Dashchyan K.A., Sazonova N.I., Mylov N.M. Recommendations of the International Society for Clinical Densitometry and Recommended Use in Clinical and Diagnostic Practice. Meditsinskaya vizualizatsiya, 2008, no. 6, pp. 84–93 (in Russ.).